Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells

Cellular Oncology

Volumn 30, Issue 6, 2008, Pages 463-471

  Lankiewicz, Silke ^a   Rother, Eva ^b   Zimmermann, Silke ^a   Hollmann, Christiane ^a,c   Korangy, Firouzeh ^b   Greten, Tim F ^b  

^a AdnaGen AG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GLAXOSMITHKLINE   (Germany)

Author keywords

Circulating tumour cells (CTC); Colorectal cancer; EGFR; EGFR variants; Immunomagnetic enrichment; RT PCR

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 54249145112     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/460457     Document Type: Article

References (31)

1. M. Azuma, K.D. Danenberg, S. Iqbal, A. El-Khoueiry, W. Zhang, D. Yang, W. Koizumi, K. Saigenji, P.V. Danenberg and H.J. Lenz, Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer, Clin. Colorectal Cancer 6 (2006), 214-218.
2. S.K. Batra, S. Castelino-Prabhu, C.J. Wikstrand, X. Zhu, P.A. Humphrey, H.S. Friedman and D.D. Bigner, Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene, Cell Growth Differ. 6 (1995), 1251-1259.
3. N.C. Bird, D. Mangnall and A.W. Majeed, Biology of colorectal liver metastases: A review, J. Surg. Oncol. 94 (2006), 68-80.
4. M.P. Bralet, B.Paule, R. Adam and C. Guettier, Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma, J. Clin. Oncol. 23 (2005), 5844-5845.
5. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, L. Schwartz, D.S. Klimstra, D. Fridman, D.P. Kelsen and L.B. Saltz, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J. Clin. Oncol. 23 (2005), 1803-1810.
6. S.J. Cohen, R.K. Alpaugh, S. Gross, S.M. O'Hara, D.A. Smirnov, L.W. Terstappen, W.J. Allard, M. Bilbee, J.D. Cheng, J.P. Hoffman, N.L. Lewis, A. Pellegrino, A. Rogatko, E. Sigurdson, H. Wang, J.C. Watson, L.M. Weiner and N.J. Meropol, Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer, Clin. Colorectal Cancer 6 (2006), 125-132.
7. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau and E. Van Cutsem, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N. Engl. J. Med. 351 (2004), 337-345.
8. J.T. den Dunnen and S.E. Antonarakis, Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion, Hum. Mutat. 15 (2000), 7-12.
9. Y.I. Elshimali and W.W. Grody, The clinical significance of circulating tumor cells in the peripheral blood, Diagn. Mol. Pathol. 15 (2006), 187-194.
10. M.M. Feldkamp, P. Lala, N. Lau, L. Roncari and A. Guha, Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens, Neurosurgery 45 (1999), 1442-1453.
11. T.F. Greten, Monoklonale Antikörper zur Behandlung kolorektaler Karzinome, Z. Gastroenterol. 42 (2004), 1413-1415.
12. A. Italiano, M.C. Saint-Paul, F.X. Caroli-Bosc, E. Francois, A. Bourgeon, D. Benchimol, J. Gugenheim and J.F. Michiels, Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications, Ann. Oncol. 16 (2005), 1503-1507.
13. Y. Kang and J. Massague, Epithelial-mesenchymal transitions: twist in development and metastasis, Cell 118 (2004), 277-279.
14. M. Koch, P. Kienle, D. Kastrati, D. Antolovic, J. Schmidt, C. Herfarth, M. von Knebel Doeberitz and J. Weitz, Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer, Int. J. Cancer 118 (2006), 3072-3077.
15. C.T. Kuan, C.J. Wikstrand and D.D. Bigner, EGF mutant receptor vIII as a molecular target in cancer therapy, Endocr. Relat. Cancer 8 (2001), 83-96.
16. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman and D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J.Med. 350 (2004), 2129-2139.
17. S. Meng, D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, A. Khan, D. Euhus, C. Osborne, E. Frenkel, S. Hoover, M. Leitch, E. Clifford, E. Vitetta, L. Morrison, D. Herlyn, L.W. Terstappen, T. Fleming, T. Fehm, T. Tucker, N. Lane, J. Wang and J. Uhr, HER-2 gene amplification can be acquired as breast cancer progresses, Proc. Natl. Acad. Sci. USA 101 (2004), 9393-9398.
18. B. Molnar, F. Sipos, O. Galamb and Z. Tulassay, Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients, Dig. Dis. 21 (2003), 320-325.
19. M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio, M. Gambacorta, S. Siena and A. Bardelli, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, Lancet Oncol. 6 (2005), 279-286.
20. D.K. Moscatello, R.B. Montgomery, P. Sundareshan, H. McDanel, M.Y. Wong and A.J. Wong, Transformational and altered signal transduction by a naturally occurring mutant EGF receptor, Oncogene 13 (1996), 85-96.
21. R. Nishikawa, X.D. Ji, R.C. Harmon, C.S. Lazar, G.N. Gill, W.K. Cavenee and H.J. Huang, A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity, Proc. Natl. Acad. Sci. USA 91 (1994), 7727-7731.
22. C.G. Rao, D. Chianese, G.V. Doyle, M.C. Miller, T. Russell, R.A. Sanders Jr. and L.W. Terstappen, Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors, Int. J. Oncol. 27 (2005), 49-57.
23. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., M.N. Needle, J. Kopit and R.J. Mayer, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J. Clin. Oncol. 22 (2004), 1201-1208.
24. A. Sarandakou, E. Protonotariou and D. Rizos, Tumor markers in biological fluids associated with pregnancy, Crit. Rev. Clin. Lab. Sci. 44 (2007), 151-178.
25. M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, G. Fabris and S. Cascinu, Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies, J. Clin. Oncol. 22 (2004), 4720-4726.
26. K.L. Spindler, D.A. Olsen, J.N. Nielsen, I. Brandslund, H.S. Poulsen, M. Villingshoj and A. Jakobsen, Lack of the type III epidermal growth factor receptor mutation in colorectal cancer, Anticancer Res. 26 (2006), 4889-4893.
27. N. Sugawa, A.J. Ekstrand, C.D. James and V.P. Collins, Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas, Proc. Natl. Acad. Sci. USA 87 (1990), 8602-8606.
28. S. Thorban, R. Rosenberg, M. Maak, J. Friederichs, R. Gertler and J.R. Siewert, Impact of disseminated tumor cells in gastrointestinal cancer, Exp. Rev. Mol. Diagn. 6 (2006), 333-343.
29. R.Q. Wharton, S.K. Jonas, C. Glover, Z.A. Khan, A. Klokouzas, H. Quinn, M. Henry and T.G. Allen-Mersh, Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples, Clin. Cancer Res. 5 (1999), 4158-4163.
30. V. Zieglschmid, C. Hollmann, B. Gutierrez, W. Albert, D. Strothoff, E. Gross and O. Böcher, Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells, Anticancer Res. 25 (2005), 1803-1810.
31. V. Zieglschmid, C. Hollmann, J. Mannel, W. Albert, S. Jaeschke-Melli, B. Eckstein, T. Hillemann, T.F. Greten, E. Gross and O. Böcher, Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer, Anticancer Res. 27 (2007), 1823-1832.